Survery of healthcare professionals to assess the awareness, knowledge and self-reported behavior regarding recent fluoroquinolones safety issues.
Romania
fluoroquinolones
health personnel
pharmacists
self report
Journal
Medicine and pharmacy reports
ISSN: 2668-0572
Titre abrégé: Med Pharm Rep
Pays: Romania
ID NLM: 101742144
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
23
11
2020
revised:
07
04
2021
accepted:
06
07
2021
entrez:
15
9
2022
pubmed:
16
9
2022
medline:
16
9
2022
Statut:
ppublish
Résumé
The impact of fluoroquinolone (FQ)-induced long-lasting, disabling, and potentially irreversible serious adverse drug reactions (ADRs) on the overall benefit-risk balance and the need for adequate risk minimization measures has been recently assessed. The present study aims to evaluate physicians and pharmacists' awareness and knowledge of the recent safety issues communicated through a direct healthcare professional communication (DHPC), regarding FQs, at a national level, in Romania, as well as healthcare professionals (HPs) self-reported behavior regarding the management of the risk. Cross-sectional, online survey study, conducted in Romania. A total of 127 participants responded to the survey. Six (4.7%) were physicians and 121 (95.3%) were pharmacists. The predominant age was 31-40 years (N=52, 40.9%), and most respondents were females (N=117, 92.1%). A majority of 101 (79.5%) were reportedly aware of the existence of the new safety issues associated with FQs, and slightly less were aware of the DHPC (N=86, 67.7%) issued in 2019. In terms of knowledge, slightly more than half of the respondents had correctly selected the responses regarding key safety messages on most important ADRs and restrictions / cautions for use. The impact of the communication on HPs self-reported behavior was high or very high in almost half of the participants (N=63, 49.6%). A high percentage of participants were aware of the FQ-associated safety concerns. Knowledge was relatively good for the key safety concerns among HPs. A notable impact on behavior was observed, mostly in terms of counselling of the patient and disseminating the information to colleagues.
Sections du résumé
Background and aims
UNASSIGNED
The impact of fluoroquinolone (FQ)-induced long-lasting, disabling, and potentially irreversible serious adverse drug reactions (ADRs) on the overall benefit-risk balance and the need for adequate risk minimization measures has been recently assessed. The present study aims to evaluate physicians and pharmacists' awareness and knowledge of the recent safety issues communicated through a direct healthcare professional communication (DHPC), regarding FQs, at a national level, in Romania, as well as healthcare professionals (HPs) self-reported behavior regarding the management of the risk.
Methods
UNASSIGNED
Cross-sectional, online survey study, conducted in Romania.
Results
UNASSIGNED
A total of 127 participants responded to the survey. Six (4.7%) were physicians and 121 (95.3%) were pharmacists. The predominant age was 31-40 years (N=52, 40.9%), and most respondents were females (N=117, 92.1%). A majority of 101 (79.5%) were reportedly aware of the existence of the new safety issues associated with FQs, and slightly less were aware of the DHPC (N=86, 67.7%) issued in 2019. In terms of knowledge, slightly more than half of the respondents had correctly selected the responses regarding key safety messages on most important ADRs and restrictions / cautions for use. The impact of the communication on HPs self-reported behavior was high or very high in almost half of the participants (N=63, 49.6%).
Conclusions
UNASSIGNED
A high percentage of participants were aware of the FQ-associated safety concerns. Knowledge was relatively good for the key safety concerns among HPs. A notable impact on behavior was observed, mostly in terms of counselling of the patient and disseminating the information to colleagues.
Identifiants
pubmed: 36105506
doi: 10.15386/mpr-1979
pii: cm-94-498
pmc: PMC9389864
doi:
Types de publication
Journal Article
Langues
eng
Pagination
498-506Références
Am Fam Physician. 2002 Feb 1;65(3):455-64
pubmed: 11858629
Drug Saf. 2018 Jul;41(7):713-724
pubmed: 29500798
Adv Ther. 2016 Feb;33(2):167-77
pubmed: 26801772
Eur J Clin Pharmacol. 2011 Jul;67(7):681-6
pubmed: 21597972
Pharmacoepidemiol Drug Saf. 2018 Jul;27(7):695-706
pubmed: 29663572
Br J Clin Pharmacol. 2018 Mar;84(3):419-433
pubmed: 29105853
BMJ. 2004 Jul 3;329(7456):44-7
pubmed: 15231627
Expert Opin Drug Saf. 2019 May;18(5):443-454
pubmed: 31032651
Drug Saf. 2010 Jun 1;33(6):463-74
pubmed: 20486729
Drug Saf. 2018 Aug;41(8):797-806
pubmed: 29671224
Eur J Clin Pharmacol. 2019 Sep;75(9):1181-1192
pubmed: 31240364
Pharmaceut Med. 2019 Apr;33(2):121-133
pubmed: 31933256
Drug Saf. 2012 Nov 1;35(11):1061-72
pubmed: 23061782